Recent Advances in Drug Development
One in eight women is
being diagnosed with breast cancer in her lifetime .Chemotherapy, which is one
of the most followed therapy for cancer results in destroying the First –line
cancer DNA-creating proteins, but BRCA genes have a backup plan that repairs
the DNA and is carried out by poly-ADP-ribose polymerases (PARPs).
The new class of breast
cancer drug Abemaciclib,
which belongs to CDK4/6 inhibitors have shown the most positive effect on
metastatic breast cancer, especially in HER2+ breast cancers .This was designed
as the breakthrough therapy Abemaciclib and is armed with certain advantages
over its rivals. The clinical studies results have put Abemaciclib roughly on
par with its competitors in the first-line setting. Side effects that occurred
in 20% or more of patients in studies were diarrhoea, nausea and vomiting,
leukopenia. Verzenio is another type of medicine which is used to treat a type
of breast cancer called HR+/HER2− (hormone receptor positive/human epidermal
growth factor receptor 2 negative) and the cancer has spread to other parts of
the body .This drug is given in combination with an aromatase inhibitor as
initial endocrine-based therapy for the treatment of postmenopausal women or
alone in women whose disease has progressed after hormone therapy and prior
chemotherapy. Another new class of drug has been developed for the LDL –Cholesterol
.The mechanism involves the lowering of cholesterol at higher levels which is
proved to be ground breaking. The experiment which is performed with statin
cholesterol drug, the new class of drugs is expected to lower cholesterol
levels by 75%.The small interfering RNA therapy to lower LDL was given twice a
year instead of monthly or weekly like other treatments. They are set to
develop new class of agents to lower the LDL levels which will be launched in
2018.
Comments
Post a Comment